Stroke Trials For New Therapies Underrepresent Women New Scientist Globally, about 14 million people have a stroke each year, and women make up about 48 per cent of cases. but women are under represented in clinical trials to test new treatments. cheryl carcel at. Clinical trials to test stroke treatments don’t include enough women, a disparity that could be hampering efforts to develop better care. globally, about 14 million people have a stroke each year, and women make up about 48 per cent of cases. but women are under represented in clinical trials to test new treatments.
Women Are Underrepresented In Stroke Trials A Comprehensive Women are disproportionately underrepresented in stroke trials relative to their burden of disease in the population, a new study reveals, while underscoring the need for clear guidance and effective strategies to boost the inclusion of participants who are women. the review of 281 trials consisting of more than half a million participants over. Abstract: the under representation of women in clinical trials is a commonly recognized and seemingly intractable problem in many different areas of clinical medicine. discrepancies in the enrollment of women in clinical trials raises concerns about the generalizability of trial evidence, as well as the potential for reduced access and utilization of new therapies in women. recent studies. A new study shows that women are underrepresented in stroke clinical trials relative to the number who have strokes in the general population. the research is published in the october 13, 2021. Although other trials of hormone therapy from europe and north america have been conducted, a summary of systematic reviews of randomized trials of hormone therapy (with major weight from whi trials) showed a cumulative small but significantly increased risk of stroke with hormone therapy (relative risk, 1.17 [95% ci, 1.05–1.29]). 5 therefore, guidelines for the prevention of cvd in women.
Reducing Under Representation Of Women In Stroke Clinical Trials The A new study shows that women are underrepresented in stroke clinical trials relative to the number who have strokes in the general population. the research is published in the october 13, 2021. Although other trials of hormone therapy from europe and north america have been conducted, a summary of systematic reviews of randomized trials of hormone therapy (with major weight from whi trials) showed a cumulative small but significantly increased risk of stroke with hormone therapy (relative risk, 1.17 [95% ci, 1.05–1.29]). 5 therefore, guidelines for the prevention of cvd in women. To quantify sex disparities in enrollment, we calculated the participation to prevalence ratio (ppr), defined as the percentage of women participating in a trial vs the prevalence of women in the disease population. results: there were 281 stroke trials eligible for analyses with a total of 588,887 participants, of whom 37.4% were women. Randomized trials have shown the benefit of endovascular thrombectomy in patients with acute stroke due to large artery occlusion in the anterior circulation and a large baseline infarct (core). 1.
Comments are closed.